ロード中...
Profile of the Pleximmune blood test for transplant rejection risk prediction
The Pleximmune™ test (Plexision Inc., Pittsburgh, PA, USA) is the first cell-based test approved by the US FDA, which predicts acute cellular rejection in children with liver- or intestine transplantation. The test addresses an unmet need to improve management of immunosuppression, which incurs grea...
保存先:
| 出版年: | Expert Rev Mol Diagn |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4965161/ https://ncbi.nlm.nih.gov/pubmed/26760313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737159.2016.1139455 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|